Skip to content
Peptigraph home

CJC-1295 + Ipamorelin vs Tesamorelin: What the Research Shows

CJC-1295 + Ipamorelin and Tesamorelin side by side: what they are, how they are regulated and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH + GHRP blendNot FDA approved · research blendCJC-1295 + IpamorelinUnapproved blend of CJC-1295 (no DAC) and ipamorelin; an FDA Drugs@FDA search for the CJC-1295 component returned no matches, so no approved product was found.[14]Growth hormonePre-mixed blendGHRH analogFDA approved (Egrifta)TesamorelinFDA-approved GHRH analog (Egrifta) for excess abdominal fat in HIV-associated lipodystrophy; visceral fat fell 15.2% versus a 5.0% rise with placebo in a randomized trial.[15]Growth hormone
Quick verdict

Where the research points

Summary of studies, not a recommendation

Consider CJC-1295 + Ipamorelin if…

No sourced contrast for this side yet. We add a point here only when it is tied to a study or label.

Consider Tesamorelin if…

  • you want a product with an FDA label: Egrifta is indicated to reduce excess abdominal fat in HIV-infected adults with lipodystrophy and is not indicated for weight loss management[9]
  • you want randomized data in HIV-associated lipodystrophy: Visceral adipose tissue fell 15.2% with tesamorelin and rose 5.0% with placebo by the end of treatment.[15]

What they have in common

  • WADA prohibits GHRH and its analogues at all times; its list names CJC-1295, sermorelin and tesamorelin[2]
CJC-1295 + Ipamorelin is not FDA approved. Both are prohibited in tested sport (WADA). Status labels come from public FDA and WADA records; see the sources below.
Side by side

Spec comparison

Showing 9 of 13 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength are the same or both unknown.

FieldCJC-1295 + IpamorelinTesamorelin
ClassGHRH + GHRP blendGHRH analog
Also calledCJC/Ipatesa, Egrifta
FDA statusNot FDA approved · research blendFDA approved (Egrifta)
Anti-doping detection
  • After nasal dosing, ipamorelin metabolites were still found in urine after the parent drug was gone (samples were collected for 2 days).PMID 25869809
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
Half-lifeIpamorelin: 2 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 1049665811 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR)
Human studies we summarised6 human (3 randomized or controlled) of 19 summarised, across ingredients12 human (11 randomized or controlled) of 16 summarised
Typical study doses
Vial sizes sold10 mg2 mg, 5 mg, 10 mg, 20 mg
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026)

Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.

Taken together?

CJC-1295 + Ipamorelin and Tesamorelin together

People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 6 results, 2 Oct 2026).

Open the stack page

CJC-1295 and ipamorelin versus tesamorelin: what the trials measured

Tesamorelin has randomized trials beyond HIV lipodystrophy. One enrolled 60 abdominally obese adults with reduced GH secretion.[16]

In that trial, tesamorelin selectively reduced visceral fat without significant effects on subcutaneous fat.[16]

In the same trial, no changes in fasting glucose, 2-h glucose or glycated hemoglobin were seen.[16]

In a randomized trial of tesamorelin in adults with mild cognitive impairment and healthy older adults, IGF-1 rose by 117% and body fat fell by 7.4%.[17]

Ipamorelin's efficacy trial found no significant differences from placebo in the key and secondary analyses.[5]

What the tesamorelin label contributes

The Egrifta WR label says to store the 11.6 mg vial at room temperature, 20°C to 25°C, in the original box to protect from light.[9]

The label says Egrifta WR is not indicated for weight loss management because it has a weight neutral effect.[9]

Common questions

CJC-1295 ipamorelin vs tesamorelin: which burns more belly fat?

Tesamorelin's randomized trials measured visceral fat, in HIV lipodystrophy and in obese adults with reduced GH secretion; it selectively reduced visceral fat in the latter.[16]

Is tesamorelin the same kind of drug as CJC-1295?

The cited trial describes tesamorelin as a GHRH(1-44) analog given at 2 mg once daily for 12 months.[16]

Does tesamorelin affect blood sugar?

In the obese-adult trial, no changes in fasting glucose, 2-h glucose or glycated hemoglobin were seen.[16]

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
  4. 4Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  5. 5Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  6. 6Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.The Journal of clinical endocrinology and metabolism · 2006PMID 16352683Accessed 2 Oct 2026
  7. 7An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  8. 8Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  9. 9EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  10. 10The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
  11. 11Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
  12. 12The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
  13. 13PubMed search: (("CJC-1295"[tiab] OR CJC1295[tiab]) AND (ipamorelin[tiab])) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14Drugs@FDA (openFDA) search: active ingredient "CJC-1295"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  15. 15Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
  16. 16Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.The Journal of clinical endocrinology and metabolism · 2012PMID 23015655Accessed 2 Oct 2026
  17. 17Effects of growth hormone–releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial.Archives of neurology · 2012PMID 22869065Accessed 2 Oct 2026

Found an error? Report a correction.